Immunosuppressants are essential to maintain transplanted organ survival and functionality, however, overimmunosuppression may lead to serious life-threatening complications such as infection and cancer. Optimal immunosuppression is warranted for the Asian, who are prone to have more infections in post-transplantation settings. However, few studies have focused on the pharmacokinetic profile of immunosuppressants in Asian transplant patients. In the era of precision medicine, individuality based on the pharmacogenomic profile is the target goal of personalized immunosuppression. Moreover, the safety and efficacy profile of generic forms should are understood in the scope of individuality.
Welcome and introduction by the Chairs
Presentation: Balances between two sides in immunosuppression: risk of rejection and infectious complications, Teun Van Gelden,The Netherlands
Live Q&A with Teun Van Gelden,The Netherlands
Presentation: Pharmacogenomic studies in Asian kidney transplantation in original and generic immunosuppressants, Jong Choel Jeong, South Korea
Live Q&A with Jong Choel Jeong, South Korea
Interactive panel discussion with audience participation led by the Chairs
Masterclass closing remarks